We just received data on a new analyst forecast for $SRPT. Brian Skorney from Baird set a price target of 35.0 for SRPT.

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sarepta Therapeutics Inc (Symbol: SRPT), where a total of 115,596 contracts have traded ...

CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 ...

The NASDAQ 100 Pre-Market Indicator is up 25.99 to 23,107.04. The total Pre-Market volume is currently 137,099,362 shares traded.The following are the most active stocks for the pre-market session ...

$260,000 of SAREPTA THERAPEUTICS INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the stocks Jim Cramer recently discussed. Sarepta Therapeutics, Inc.

The S&P 500 Index ($SPX) (SPY) today is up +0.48%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.39%, and the Nasdaq ...

We recently published 12 Stocks Jim Cramer Discussed As Analyzed Morgan Stanley’s Comments. Sarepta Therapeutics, Inc.

Sarepta Therapeutics (SRPT) is down more than -14% after it said another patient died from acute liver failure after receiving one of its experimental gene therapies for a muscle disease.

Sarepta Therapeutics (SRPT) is down more than -18% after it said another patient died from acute liver failure after receiving one of its experimental gene therapies for a muscle disease.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the most undervalued stocks to buy and hold for 3 years. On July 22, BMO ...

Sarepta Therapeutics (SRPT) is down more than -4% after it refused to pause all shipments of its Elevidys treatment after three deaths were linked to the company’s gene therapies.